相关实验视频

Updated: May 3, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

免疫系统用质子对光子放射疗法治疗局部先进的NSCLC

Jimmy S Patel¹, Neal S McCall², Matthew Thomas¹

¹Department of Radiation Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA.

International journal of particle therapy

|June 4, 2024

概括

与强度调节放射治疗 (IMRT) 相比,强度调节质子疗法 (IMPT) 在非小细胞肺癌 (NSCLC) 患者中显著降低了对免疫细胞 (EDIC) 的有效辐射剂量. 这种减少可能会改善NSCLC治疗的整体存活率.

科学领域:

辐射瘤学辐射瘤学
医学物理医学物理
在瘤学瘤学.

背景情况:

免疫细胞的有效辐射剂量 (EDIC) 是癌症治疗中的新兴预后因素.
局部发达,无法切除的非小细胞肺癌 (NSCLC) 需要先进的放射治疗技术.
强度调节放射治疗 (IMRT) 是一种标准治疗方法,但它对免疫细胞的影响令人担忧.

研究的目的:

在NSCLC患者中,比较强度调制质子疗法 (IMPT) 和强度调制放射疗法 (IMRT) 之间的免疫细胞有效辐射剂量 (EDIC).
调查IMRT与IMRT相比,IMPT是否可以减少EDIC.
评估减少EDIC对整体存活时间的潜在影响.

主要方法:

对12名医生批准的IMRT和IMPT计划的NSCLC患者进行了回顾性剂量分析.
使用已建立的模型计算EDIC (Jin等. 和拉德伯里等人. ) 的情况.
用于比较IMPT和IMRT计划之间的平均EDIC的配对t测试.

主要成果:

在12名患者中有11名 (91.7%) 的患者中,IMPT导致EDIC的统计显著减少.
与IMRT相比,IMPT的平均EDIC显著低于IMRT (Jin模型:3.04 GyE与4.99 Gy;拉德伯里模型:4.50 GyE与7.60 Gy).
与IMRT (63%) 相比,模拟的2年整体存活时间在IMPT (71%) 中显着更长.

结论:

与IMRT相比,强度调节质子疗法 (IMPT) 显著降低了对免疫细胞 (EDIC) 的有效辐射剂量.
通过IMPT减少EDIC突出了其改善NSCLC瘤结果的潜力.
IMPT可能会解决改善局部区域性晚期NSCLC患者存活率的未满足需求.

关键词:

埃迪克电讯 (EDIC) 是一个电子通讯系统.在NSCLCLC中,我们可以看到.光子光子是一种光子.质子质子质子

更多相关视频

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine

Author Spotlight: Radiotherapy and Clonogenic Assays for Advancing Cancer Research and Personalized Medicine

Published on: April 5, 2024

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.